Company research / PODD

Insulet Corp (PODD)

SEC name INSULET CORP · CIK 0001145197 · Nasdaq · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Insulet Corp reported revenue of $2.71B. Revenue grew 30.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $3.05B.

Key ratios (year ended 2025-12-31)

71.6%
Gross margin
17.5%
Operating margin
9.1%
Net margin
16.3%
Return on year-end equity
30.7%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-05

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$3.05B$2.71B$2.07B$1.70B$1.31B$1.10B$904.40Mn/an/a$463.77M$366.99M
Cost of Revenue$883.20M$768.20M$625.90M$537.20M$499.70M$346.70M$322.10M$257.90M$193.60M$186.60M$155.90M
Gross Profit$2.17B$1.94B$1.45B$1.16B$805.60M$752.10M$582.30M$480.30M$370.20M$277.20M$211.09M
R&D Expense$345.90M$301.10M$219.60M$205.00M$180.20M$160.10M$146.80M$132.30M$94.80M$75.70M$55.71M
Operating Income$515.70M$473.80M$308.90M$220.10M$37.60M$126.00M$51.50M$50.00M$27.40M-$7.40M-$10.70M
Depreciation & Amortization$99.30M$90.40M$80.80M$72.80M$63.20M$57.40M$55.40M$27.90M$15.60M$13.90M$13.83M
EBITDA$615.00M$564.20M$389.70M$292.90M$100.80M$183.40M$106.90M$77.90M$43.00M$6.50M$3.13M
Net Income$375.30M$247.10M$418.30M$206.30M$4.60M$16.80M$6.80M$11.60M$3.30M-$26.80M-$28.88M
EPS (Diluted)n/a$3.48$5.78$2.94$0.07$0.24$0.10$0.19$0.05-$0.46-$0.48
Total Assets$3.17B$3.19B$3.09B$2.59B$2.25B$2.05B$1.87B$1.14B$928.70M$816.74M$456.65M
Total Liabilities$1.74B$1.68B$1.88B$1.86B$1.77B$1.49B$1.27B$1.07B$716.60M$658.23M$393.50M
Long-Term Debtn/an/an/an/a$1.40B$1.27B$1.06B$887.90M$591.98M$566.17M$332.77M
Shareholders' Equity$1.42B$1.52B$1.21B$732.70M$476.40M$556.30M$603.60M$75.90M$212.10M$158.50M$63.15M
Cash & Equivalentsn/an/an/an/an/an/a$907.20M$213.70M$113.90M$272.58M$137.17M
Operating Cash Flow$511.20M$569.30M$430.20M$145.70M$119.00M-$68.10M$84.00M$98.40M$35.90M$41.30M$15.91M
Capital Expenditures$217.50M$191.60M$124.90M$75.60M$122.90M$111.90M$129.00M$163.70M$157.40M$73.80M$22.11M
Free Cash Flow$293.70M$377.70M$305.30M$70.10M-$3.90M-$180.00M-$45.00M-$65.30M-$121.50M-$32.50M-$6.20M
Share Repurchases$329.50M$59.60M$0$0n/an/an/an/an/an/an/a
Shares Outstandingn/a70.39M70.20M69.91M69.51M69.18M66.02M62.69M59.19M58.32M57.46M
Weighted Average Diluted Sharesn/a71.89M73.89M73.63M69.91M68.58M65.95M62.30M61.01M58.00M57.25M
EPS (Basic)n/a$3.51$5.97$2.96$0.07$0.25$0.11$0.19$0.06-$0.46-$0.48

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView